Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 6440983 | Cholestatic jaundice induced by gold salts treatment clinical and immunological aspects--r | 1984 Dec | Hepatotoxicity is a rare complication of treatment with gold salts. The clinical and laboratory features are those of cholestatic jaundice and other diagnostic possibilities must be ruled out. Gradual recovery after withdrawal of the drug is the rule. We report a case and review previous literature with emphasis on the diagnostic value of the lymphocyte transformation test. | |
| 6690768 | Pulmonary infiltrates associated with naproxen. | 1984 Jan 6 | Pulmonary infiltrates developed in three middle-aged women while receiving naproxen sodium. Weakness, fatigue, cough, low-grade fever, and eosinophilia in blood and/or sputum were common to all. All symptoms and findings resolved within a few days after discontinuing naproxen therapy in two cases and with use of corticosteroids (prednisone) in one case. A hypersensitivity reaction due to naproxen seemed to be the likely cause. | |
| 6354111 | Serum antibodies to type II collagen in rheumatoid arthritis: comparison of 6 immunologica | 1983 Oct | A collaborative study of 75 selected patients with rheumatoid arthritis (RA) employing 6 different methods for the detection of antibodies to type II collagen showed highly significant correlations between all the assays. The radioimmunoassays showed a greater sensitivity than either the passive haemagglutination or immunofluorescent techniques, and when the native collagen molecule was heat-denatured a higher number of patients showed increased antibody levels. In 33 patients the measurement of serum antibody levels to human, bovine, and rat native type II collagen showed a lack of species specificity, indicating that heterologous collagens can be employed in these assays. A retrospective analysis of the clinical, laboratory, and radiological features in the 41 patients with raised antibody levels and the 34 patients with normal antibody levels showed very few differences, but there was a significantly lower incidence of subcutaneous nodules (24% versus 56%) in patients with raised antibody levels. This study emphasizes the need to standardize assays for the measurement of serum antibody levels to native type II collagen. More extensive studies will be required before the clinical significance of these antibodies can be fully established. | |
| 6345165 | Mechanism of action of drugs for treating inflammation and arthritis. | 1983 | The mechanism of action of various types of drugs for treating inflammation and arthritis is reviewed. Three classes of agents, the steroidal, the acidic non-steroidal and the basic therapy drugs, are discussed. The first two types of drugs act rapidly on the symptoms of inflammation, interfering at various points in the inflammatory response. The non-steroidal agents are especially linked to a mechanism involving, at least in part, the prostaglandins. Piroxicam, a potent, structurally unique member of the non-steroidal class, is discussed in some detail. The basic therapy drugs act slowly, generally exhibit more severe side effects and probably affect some immunological aspects of rheumatoid arthritis. The precise mechanisms of action of this latter class of structurally diverse drugs is generally poorly understood at this time. | |
| 6792737 | A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. | 1981 Jun 30 | Information was obtained by questionnaire about 215 non-hemophilic patients who developed inhibitors against factor VIII (antihemophilic factor). The majority of the patients were over 50 years of age, and approximately equal numbers of males and females were reported. Rheumatoid arthritis was present in 8% of the cases, 7% occurred during pregnancy or the post-partum period, and in several there was an association with allergy to penicillin, asthma, "auto-immune" diseases, or malignancy. In 46% of cases, no underlying disorders were identified. Major bleeding was observed in 87% of patients, and in 22%, death was attributed either directly or indirectly to the presence of the inhibitor. In 11 of 31 patients receiving no therapy other than supportive transfusions of blood or factor VIII concentrate, the inhibitor disappeared after being present for an average duration of 14 months. Corticosteroids were thought to be effective in abolishing the inhibitor in 22 of 45 patients in whom these were the only drugs administered. Twenty-eight patients received azathioprine as well as corticosteroids; in 19, the inhibitor declined or disappeared during treatment. Finally, 80 patients were treated with cyclophosphamide; in 37 there was a favorable outcome. Inhibitors in children and post-partum patients were more likely to disappear spontaneously or with steroid therapy, whereas those in patients with rheumatoid arthritis or other "autoimmune" disorders required treatment with alkylating agents. However, before any specific therapy can be recommended for this disorder, prospective trials of potential therapeutic agents should be conducted in selected subgroups. | |
| 4009026 | Immunoassay for IgG rheumatoid factor with a murine monoclonal anti-Fd antibody. | 1985 Jul | Conventional radioimmunoassays for IgG rheumatoid factors (RF) detect the binding of IgG RF (or their F(ab')2 fragments) to solid-phase human IgG Fc fragments or rabbit IgG. Binding is detected with a radiolabeled antibody that is IgG-specific but is nonreactive with human Fc (i.e., an alpha-Fd reagent) or with rabbit IgG. Anti-Fd reagents are quite laborious to produce. We developed a murine monoclonal alpha-Fd antibody, confirmed its specificity, and compared it with conventional rabbit alpha-Fd in the IgG RF radioimmunoassay. We also adapted the assay to an enzyme-linked assay with both human Fc and rabbit IgG as antigen. We compared the four assay methods with each other and examined their relationship to certain clinical and laboratory features of rheumatoid arthritis. | |
| 3882061 | A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. | 1985 Jan | The efficacy of diltiazem in the treatment of Raynaud's phenomenon was assessed in a prospective double-blind randomised cross-over trial in 16 patients (7 progressive systemic sclerosis, 2 rheumatoid arthritis, 1 systemic lupus erythematosus, and 6 idiopathic Raynaud's phenomenon). Each patient received diltiazem 120 mg and placebo three times a day for two weeks. The attack frequency of Raynaud's phenomenon was measured by a diary count; its severity was assessed by means of a 10 cm visual analogue scale with 0 representing minimum and 10 representing maximum severity. Diltiazem significantly decreased the frequency and severity of Raynaud's phenomenon as compared with placebo. This improvement was striking in patients with idiopathic Raynaud's phenomenon but did not reach statistical significance in patients with associated systemic disease. We conclude that diltiazem is effective in the treatment of Raynaud's phenomenon, especially in patients with idiopathic vasospastic disease. | |
| 7042366 | Results of a double-blind study with indomethacin and indoprofen, a new non-steroidal anti | 1981 | Indoprofen, a new non-steroidal antirheumatic agent, was tested in a controlled, double-blind, cross-over study versus indomethacin and placebo, in 30 patients with rheumatoid arthritis. The study consisted of three fourteen-day treatment periods. At the end of the trial 14 patients expressed a preference for the indoprofen therapy (200 mg q.i.d.), 10 patients for indomethacin (25 mg q.i.d.) and 5 patients decided in favour of the placebo. Judging from the patients' assessment of spontaneous pain, a complete analgesic effect was observed in 44% of the patients under indoprofen, in 26% under indomethacin and in 13% under placebo. Indoprofen showed good efficacy on all the other parameters measured (Ritchie's index, morning stiffness, number of painful and swollen joints, and grip strength) and good clinical and biological safety. | |
| 2414688 | [Effect of methisoprinol on neutrophil functions in patients with rheumatoid arthritis]. | 1985 Oct 27 | Neutrophils and monocytes are fundamental to the inflammatory process. They migrate into inflammatory foci where they manufacture and release numerous substances (enzymes X O2 ions) which if not controlled may injure the tissues they come in contact with. This enhanced response is responsible for the degenerative reaction typical of inflammation which occurs in rheumatoid arthritis. neutrophil and monocyte metabolism are activated in response to various drugs or to chemicals that may be produced either by the inflammatory agents or by other immunocompetent cells. Hence, immune system modulators may be employed to control their response. For this reason neutrophil and monocyte function was studied in subjects with rheumatoid arthritis as was the ability of methisoprinol, a major immunomodulating drug, to control their functional response both in vivo and in vitro. Neutrophils present a defective chemotactic activity attributable to a circulating inhibitory factor, a defect that methisoprinol can correct. The drug also stimulates lymphocytes and monocytes to produce substances that activate neutrophil chemotaxis. Methisoprinol is an excellent drug that can modify the altered cell-mediated immunity of rheumatoid arthritis patients. | |
| 477107 | An uncemented total hip replacement: experimental study and review of 300 madreporique art | 1979 Jun | Mafreporique arthroplasty is not intended as a bustitute for acrylic cement stabilized arthroplasty but is available as an effective alternative. An experimental and clinical investigation including radiological analysis of 300 madreporique arthroplasties has convinced us of the reality and reliability of biological anchoring by endosteal osteogenesis. The madreporique method does not result in any local or general complications usually associated with the cement technique. Full weight-bearing is permitted at the same postoperative time as the cemented prosthesis. The results at early and interim follow-up periods compare favorably with cemented hip arthroplasties. Living bone that undergoes remodelling provides for long-term anchor of the prosthesis and eliminates the chemical intermediary which leads, more or less, with time to loosening of the implant in a significant number of cases. | |
| 488776 | Trapezio-metacarpal arthroplasty by total prosthesis. | 1979 Feb | Thirty-four total trapezio-metacarpal prostheses have been fitted since 1971. Twenty-eight have had a follow-up for more than six months (up to a maximum of five years) and allow a valid assessment of the situation. The operations were undertaken for rheumatoid, osteoarthritic disease, and following trauma. The reasons were either pain, mechanical instability, or stiffness. Two out of three times results were good. The best results were obtained for pain and stability. Those where the indication was stiffness were less satisfying. There were five cases of loosening of the trapezial cup due to operative errors. The mediocre results in general are caused by incomplete treatment allowing an associated lesion to develop. Greater strictness in the indications and in carrying out of operation ought to ensure better results. | |
| 3000352 | Purification of a metalloproteinase inhibitor from human rheumatoid synovial fluid. | 1985 Nov 1 | A metalloproteinase inhibitor present in human rheumatoid synovial fluid was purified by a combination of heparin-Sepharose chromatography, concanavalin A-Sepharose chromatography, ion-exchange chromatography and gel filtration. The Mr of the purified inhibitor was 28000 by SDS/polyacrylamide-gel electrophoresis and 30000 by gel filtration. The inhibitor blocked the activity of the metalloproteinases collagenase, gelatinase and proteoglycanase, but not thermolysin or bacterial collagenase. The serine proteinase trypsin was not inhibited. The inhibitory activity was lost after treatment with trypsin (0.5 micrograms/ml) at 37 degrees C for 30 min, 4-aminophenylmercuric acetate (1 mM) at 37 degrees C for 3 h, after incubation for 30 min at 90 degrees C and by reduction and alkylation. These properties suggest that the inhibitor closely resembles the tissue inhibitor of metalloproteinases ('TIMP') recently purified from connective-tissue culture medium. | |
| 6380279 | Update on ibuprofen for rheumatoid arthritis. | 1984 Jul 13 | In doses of 1,200 mg/day or more, ibuprofen is as effective as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of rheumatoid arthritis. The tolerability and safety of ibuprofen are superior to those of aspirin and compare favorably with those of other NSAIDs. Although additional controlled trials are indicated to determine optimal dose, ibuprofen's excellent therapeutic index establishes it as a useful drug in the treatment of rheumatoid arthritis. | |
| 3903778 | Comparison of naproxen and piroxicam in the treatment of rheumatoid arthritis: a double-bl | 1985 | A double-blind, crossover study was carried out in 50 patients with rheumatoid arthritis to compare the efficacy and tolerance of single evening doses of 1000 mg naproxen and 20 mg piroxicam. After an initial wash-out period of 1 week, patients received 4-weeks' treatment with one or other of the trial drugs and were then crossed over after a 1-week wash-out period to the alternative medication for a further 4 weeks. Objective assessments of disease activity and patients' and physician's assessments of therapeutic response were made at the end of each wash-out and active treatment period, and at the end of the trial patients and physician were asked to say which of the two active treatments was preferred. Forty-nine patients completed the 10-week trial; one patient discontinued the study while on piroxicam therapy because of side-effects. While both treatments proved effective, naproxen was statistically significantly better than piroxicam for total joint pain, grip strength, duration of morning stiffness, and overall therapeutic response. Naproxen also had a more rapid and more pronounced action than did piroxicam and was selected as the preferred drug by both patients and physicians. Patients taking naproxen reported slightly fewer side-effects than did those taking piroxicam. | |
| 2578833 | [Protein, RNA and DNA synthesis in skin fibroblast cultures from healthy donors and patien | 1985 Feb | Synthesis of protein, RNA and DNA was studied in skin fibroblast cultures of healthy donors and patients with systemic scleroderma (SSD) and in those with rheumatoid arthritis (RA) with the use of 14C-protein hydrolyzate, 14C-uridine and 14C-thymidine, respectively. A study was also made of the stimulation of 14C-proline incorporation in protein fibroblasts upon addition to serum-free media of 5% bovine embryonic serum. The stability of RNA in fibroblasts was tested. It was shown that the rate of protein synthesis was 11 times higher in fibroblasts of RA patients and 6 times higher in those of SSD patients as compared to the rate of protein synthesis in fibroblasts of normal subjects. The rate of DNA synthesis in skin fibroblasts of RA patients was 15 times higher and in those of SSD patients 4 times higher than normal. In both RA and SSD patients, the synthesis of short-labeled RNA was 2-3 times higher than normal. The addition of embryonic serum increased 2-3 times the incorporation of 14C-proline in protein skin fibroblasts of SSD patients. It was found that all RNA in skin fibroblasts was represented by long-living molecules and that 30-40% of short-labeled RNA in skin fibroblasts of healthy donors and SSD patients underwent degradation within 1-2 hours. The data obtained indicate that fibroblasts of the two pathologies under study are characterized by considerable differences in the synthesis of DNA and the activity of the protein-synthesizing system. | |
| 3886223 | Immunoglobulin subclass distribution of synovial plasma cells in rheumatoid arthritis dete | 1985 Jun | The distribution of IgG and IgA subclass plasma cells among dissociated synovial cells from 14 rheumatoid arthritis (RA) synovia was examined by immunofluorescence using mouse monoclonal anti-human subclass antibodies. Of the IgG plasma cells 81 +/- 9% were IgG1, 4 +/- 2% IgG2, 14 +/- 9% IgG3, and 0.9 +/- 0.6% IgG4. While IgG1 predominated in all 14 synovia (which is similar to what is seen in normal tissues), in 5/14 20% or greater of IgG plasma cells were IgG3, suggesting a selective increase in IgG3 production in the synovia of certain RA patients. Among IgA plasma cells 89 +/- 5% were IgA1 and 8 +/- 3% were IgA2. This distribution is similar to the distribution in normal serum. | |
| 6367527 | Antibodies against nuclear components in schistosomiasis. Results compared to values in pa | 1984 Feb | Occurrence of autoantibodies against nuclear material was compared in groups of patients with rheumatoid arthritis (RA n = 22), systemic lupus erythematosus (SLE n = 24), osteoarthrosis (OA n = 25), and chronic schistosomiasis mansoni (CSM n = 28). Anti-ds DNA antibody was detected by an ammonium sulphate precipitation radioimmunoassay antibodies against extractable nuclear antigen (ENA) were detected and differentiated in RNAse-resistant and RNAse-sensitive components (Sm and RNP antigens) with an ELISA technique. IgG organ-non-specific and granulocyte-specific antinuclear antibodies (ANA) were detected by immunofluorescence technique with quantitative titration of positive reactions and determination of complement-fixing properties. The results in groups of patients with SLE, RA and OA were of confirmative nature and supported that the different methods detect different systems of autoantibodies and nuclear autoantigens. In CSM it was demonstrated that 23 of 28 cases had positive reactions to the RNAse-resistant part of ENA (the Sm-antigen), a significant difference from the three other groups of patients (P less than 0.001). The antibody was in all cases of IgM class, in seven cases also of IgA class. Antibodies against nuclear material in CSM are probably a consequence of heavy disturbance of the immune system in this chronic infection with great permanent antigen load. It is a matter of discussion, whether production of these antibodies is induced by nuclear material from the host or from the parasite. | |
| 6751631 | An immunohistological analysis of lymphocyte subpopulations and their microenvironment in | 1982 Jul | We have used monoclonal antibodies of the orthoclone (OKT) series to identify T cell subsets in an immunohistological analysis of the synovial membranes obtained from normal individuals and patients with osteoarthritis or rheumatoid arthritis. T cells of the inducer and the suppressor/cytotoxic subsets were identified by the OKT4 and OKT8 antibodies respectively while HLA-DR (Ia-like) antigens were recognized by a conventional antiserum. In the normal and osteoarthritic synovial membranes, virtually no lymphocytes were identified whereas the mononuclear cell infiltrates of the rheumatoid synovial membranes were composed predominantly of T cells expressing the OKT4 inducer phenotype with few OKT8+ suppressor/cytotoxic cells. The OKT4+ cells were found to be intimately related to B cells and strongly HLA-DR+ cells which morphologically resembled the interdigitating cells of lymph nodes. The micro-anatomical arrangement of these different cell types in the mononuclear infiltrates of the rheumatoid synovial membranes closely resembled that of the paracortical or T cell dependent area of normal lymph nodes except few OKT8+ lymphocytes were present. These findings are explained in terms of rheumatoid arthritis as a disease of altered T lymphocyte/macrophage immunoregulation. | |
| 3922461 | Copper chelates of antirheumatic and anti-inflammatory agents: their superoxide dismutase- | 1985 May | An in vitro assay is described which simultaneously tests for the superoxide dismutase-like activity of low-molecular-weight copper chelates and their stability in the presence of excess EDTA. The EDTA is introduced to simulate the competitive endogenous ligands a copper-chelating drug will encounter in plasma and other body fluids. Under the conditions of the assay, antirheumatic drugs of the D-penicillamine type are clearly distinguished both from nonsteroidal anti-inflammatories and from some drugs which chelate copper but lack antirheumatic activity. | |
| 729270 | Cement-free bioceramic double-cup endoprosthesis of the hip-joint. | 1978 Jul | A cement-free bioceramic aluminum oxide double cup endoprosthesis is under investigation as an alternative to the cemented stem endoprosthesis. Nine patients with 11 operated hips are without complaints after an average of 20.8 months (range 8--28 months). Early loosening of 2 femoral components occurred because of technical mistakes during operation. In 3 patients loosening of the femoral component was seen 5--7 months after surgery. Mobilization of the hip joint and walking capacity are similar to the usually implanted stem endoprosthesis. Stable long-lasting anchorage is possible if the femoral component is implanted in valgus position and in contact with living bone. Failures are treated by a traditional type of endoprosthesis. |